Funding for this research was provided by:
Received: 27 August 2020
Accepted: 4 March 2021
First Online: 22 March 2021
: The study was conducted in accordance with the protocol, International Conference for Harmonization (ICH), Good Clinical Practice (GCP), FDA regulations govering clinical study conduct, ethical principles that have their origins in the D, declaration of Helsinki, 1996 and 2000 revisions with subsequent clarification, and all applicable local regulations. Before the study was initiated, the study protocol, the informed consent form and the subject information were submitted for review to the responsible independent ethics committee of the Aerztekammer Nordrhein, Duesseldorf, Germany, reference number 2/2015/7441. Parents/legal guardians signed the informed consent form before any study-related procedures occurred.
: Not applicable
: AR has no conflict of interest. AK has received congress travel fees from Sobi, Sandoz and advisory board honoraria from Celgene. DH has no conflict of interest. FD has received speaker’s fees from Abbvie, Novartis and Pfizer. FWH: has no conflict of interest in regard to this study.GH has received unrestricted funding from Abbvie, Chugai, MSS, Pfizer, Novartis and Roche and personal fees from Bayer, Sobi, Novartis and Pfizer. IF participated on: advisory boards BMS, Amgen, Novartis, Chugai, Abbvie and Pfizer. JKD has no conflict of interest in regard to this study. TK has no conflict of interest in regard to this study.